Multiple-pulse drug delivery systems: Setting a new paradigm for infectious disease therapy

Expert Opinion on Drug Delivery

Volumn 6, Issue 4, 2009, Pages 441-452

  Saigal, Nitin ^a,b   Baboota, Sanjula ^a,b   Ahuja, Alka ^a,b   Ali, Javed ^a,b  

^a HAMDARD UNIVERSITY   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Biological tolerance; Chronotherapeutics; Coating; Delayed release; Drug fractions; Eudragits; Lag time; Multiple pulse delivery; Pellets; PULSYS ; Single pulse

Indexed keywords

AMOXICILLIN; AMOXICILLIN PULSYS; ANTIBIOTIC AGENT; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; EUDRAGIT; FLUTAMIDE; IBUPROFEN; MESALAZINE; METHYLPHENIDATE; METRONIDAZOLE; PENICILLIN G; POLY(METHYL METHACRYLATE);

ACUTE OTITIS MEDIA; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BACTEROIDES INFECTION; BIOLOGY; CHRONIC BRONCHITIS; CLINICAL STUDY; CLINICAL TRIAL; DESTRUCTION; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENTERITIS; HUMAN; INFECTION; INSOMNIA; MICROORGANISM; PHARYNGITIS; PROSTATE CANCER; REVIEW; SINUSITIS; STAPHYLOCOCCUS INFECTION; TABLET; TECHNOLOGY; TONSILLITIS; URINARY TRACT INFECTION;

ANTI-INFECTIVE AGENTS; COMMUNICABLE DISEASES; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MICROBIAL; HUMANS; MEDICATION ADHERENCE; PULSE THERAPY, DRUG; TECHNOLOGY, PHARMACEUTICAL;

EID: 67649119513     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240902895972     Document Type: Review

References (73)

1. Lambert P. Antibiotic resistance: a challenge for the industry. Ind Pharm 2006;10:6-7[Cited 3 Jan 2009]. Available from: www.industrialpharmacy.com
2. Charles Darwin theory of evolution. Brief summary. On truth and reality, 2009. Available from: http://www.spaceandmotion.com/Charles-Darwin-Theory- Evolution.htm [Cited 15 Jan 2009]
3. Darwin's theory of evolution: a theory in crisis. All about science, 2008. Available from: http://www.darwins-theory-of-evolution.com/ [Cited 25 Jan 2009]
4. Greenwood D, Finch R, Davey P, et al. Antimicrobial chemotherapy. Fifth edition. Oxford University Press, 2007
5. Todar K. Bacterial resistance to antibiotics. Todar's online textbook on bacteriology, 2008. Available from: http://www.textbookofbacteriology.net [Cited 20 Dec 2008]
6. Brigham N. World of microbiology and immunology. Thomson Gale Press, 2006;2
7. Zahnel G, Hoban D, Harding G. The post-antibiotic effect: a review of in vitro and in vivo data. Ann Pharmacother 1991;25:153-163
8. Formulation boosts antibiotic efficacy. Decision News Media, 2004. Available from: http://www.in-pharmatechnologist.com/Materials-Formulation/ Formulation-boosts-antibiotic-efficacy [Cited 3 Jan 2009]
9. Forward-looking statements form 10-K. Middlebrook Pharmaceuticals Business Inc., 2008. Available from: http://google.brand.edgar-online.com [cited 5 Jan 2009] • Ready reference for all Middlebrook and Moxatag developments.
10. Michiu K. Multiple-delayed release formulation approach for the treatment of methicillin-resistant Staphylococcus aureus. Exp Opin Ther Pat 2008;18:1313-1319
11. Sun H, Lee S, Banevicius M, et al. Efficacy of pulsatile amoxicillin and clarithromycin dosing alone and in combination in a murine pneumococcal pneumonia model. J Antimicrob Chemother 2005;56:559-565 (Pubitemid 41264136)
12. New antibiotics developments are on the horizon. Middlebrook Pharmaceuticals, 2007. Available from: http://www.advancispharm.com/PIPE-new- antibiotics. [Last accessed 8 January 2009]
13. Magruder P, Barclay B, Wong P, Theeuwes F. Composition comprising salbutamol. US4751071; 1988
14. Gazziranga A, Giordano F. Delayed release systems (DRS) based on retarding swellable hydrophilic coating. Proc 12 Pharmaceutical International Technology Conference 1993;1:400-408
15. Gazziranga A, Iamatrino P, Sangalli M. Oral delayed release system for colon specific delivery. Int J Pharm 1994;108:77-83 (Pubitemid 24207344)
16. Conte U, Maggi L. Modulation of the dissolution profiles from Geomatrix multi-layer matrix tablets containing drugs of different solubility. Biomaterials 1996;17:889-896 (Pubitemid 26136568)
17. Conte U, Maggi L. Geomatrix tablets for the pulsatile release of drugs. Proc Int Symp Control Release Bioactive Mater 1997;24:291-292 (Pubitemid 27336523)
18. Conte U, Maggi L, La Manna. Pharmaceutical tablet capable of releasing the active ingredients contained therein at subsequent times. US5650169; 1997
19. Pozzi F, Furlani P, Gazziranga A, et al. The time clock system: a new oral dosage form for fast and complete release of drug after predetermined lag time. J Control Release 1994;31:99-108 (Pubitemid 24248121)
20. Held K, Marolf T, Erni W. Principle and development of a tablet formulation with pulsatile drug delivery after a controlled and pH dependent latency period. Acta Pharm Technol 1990;36:38s
21. Stevens HNE. Chronopharmaceutical drug delivery. J Pharm Pharmacol 1998;50:s5
22. Stevens HNE, Chariot M, Arnold F, Lewis GA. Sustained release pharmaceutical compositions of diltiazem. US5112621; 1992
23. Ueda Y, Hata T, Yamaguchi H, et al. Time-controlled explosion systems. US4871549; 1989
24. Chen CM. Pulsatile particles drug delivery system. US5260069; 1993
25. Rashid A. Dispensing device. EP0384642; 1990
26. Crison JR, Siersma PR, Taylor MD, Amidon GL. Programmable oral release technology PORT system: a novel dosage form for time and site specific oral drug delivery. Proc Int Symp Control Release Bioactive Mater 1995;22:278-279
27. McNeill ME, Rashid A, Stevens HNE. Drug dispensing device. GB2230442; 1993
28. Wong PSL, Theeuwes F, Larsen SD. Osmotic device for delayed delivery of agent. US5312388; 1994
29. Ross AC, MacRae RJ, Walther M, Stevens HNE. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. J Pharm Pharmacol 2000;52:903-909 (Pubitemid 30686195)
30. Niwa K, Takaya T, Morimoto T, Takada K. Preparation and evaluation of a time controlled release capsule made of ethyl cellulose for colon delivery of drugs. J Drug Target 1995;3:83-89
31. Stevens HNE, Ross AC, Johnson JR. The hydrophilic-sandwich (HS) capsule: a convenient time delayed oral probe device. J Pharm Pharmacol 2000;52:s41
32. Flanner H, Treasy D, Ebrahim S, et al. Gastric release pulse system for drug delivery. WO079082; 2007
33. Flanner H, Treasy D, Ebrahim S, et al. Gastric release pulse system for drug delivery. US0154547; 2007
34. Klein S, Stein J, Dressman J. Site specific delivery of anti-inflammatory drugs in the gastrointestinal tract: an in vitro release model. J Pharm Pharmacol 2005;57:709-719 (Pubitemid 40694878)
35. Lerner I, Flashner M, Penhasi A. Immediate release gastrointestinal drug delivery system. US6531152B1; 2003 • Patent giving solutions for issues related to slow release after lag phase.
36. Huyghebaert N, Vermeire A, Remon JP. In vitro evaluation of coating polymers for enteric coating and human ileal targeting. Int J Pharm 2005;298:26-37
37. Chang R, Shah N. Two or more enteric materials to regulate drug release. WO062557; 2004
38. Gupta V, Beckert T, Price J. A novel pH and time-based multi-unit potential colonic drug delivery system. Int J Pharm 2001;213:83-91 (Pubitemid 32119464)
39. Kastra W, Cima M, Palazzolo B, et al. Oral dosage form by three dimensional printing. Proc Int Symp Control Release Bioactive Mater 1998;25:760-761 (Pubitemid 28336827)
40. Kastra W, Rowe A, Teung P, Cima M. Pulsatory oral drug delivery devices fabricated by three-dimensional printing. Proc Int Symp Control Release Bioactive Mater 1999;26:569-570
41. Li Y, Zhu J. Modulation of combined release behaviors from a novel 'tablets in capsule system'. J Control Release 2004;95:381-389
42. Li Y, Zhu J, Gong W. A novel system for three-pulse drug release based on 'tablets in capsule' device. Int J Pharm 2007;352:159-164
43. El-Mallah Y, Nazzal S. Novel use of Eudragit NE30D/Eugragit L30D55 blend as functional coating materials in time delayed release application. Int J Pharm 2008;357:219-227
44. Ibrahim K, Gunderson R, Laurie B, et al. Pharmacodynamics of pulse dosing versis standard dosing: in vitro metronidazole activity against Bacteroides fragilis and B. theteiotamicron. Antimicrobial Agents Chemother 2004;48:4195-4199 (Pubitemid 39434875)
45. Stupak E, Cho P. Controlled release flutamide composition. US5162117; 1993
46. Chen C. Pulsatile particles drug delivery system. US5260069; 2001
47. Lerner I, Flashner M. Immediate release gastrointestinal drug delivery system. WO9918938; 1999
48. Percel P, Vishnupad K, Krishna S. Timed Pulsatile drug delivery systems. US7048945; 2003
49. Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/ hyperactivity disorder: expected cost analysis. Clin Ther 2001;23:1904-1921 (Pubitemid 33121978)
50. Conte U, Colombo P, La Manna A, et al. A new ibuprofen pulsed release oral dosage form. Drug Dev Ind Pharm 1989;15:2583-2596 (Pubitemid 20027611)
51. MiddleBrook Pharmaceuticals to Launch Moxatag March 2009. Logistics Online, 2009. Available from: http://www.logisticsonline.com/article.mvv. [Last accessed 26 January 2009]
52. Moxatag Consumer Information. Drug information online, 2009. Available from: http://www.drugs.com/moxatag.html. [Last accessed 20 January 2009]
53. Highlights of prescribing information. MOXATAG™ (amoxicillin extended-release) Tablets, 2009. Available from: www.fda.gov/cder/foi/label/ 2008/050813lbl.pdf. [Last accessed 21 January 2009]
54. Adis International. Amoxicillin Pulsatile - MiddleBrook: APC 111, APC-111, PULSYS-Enhanced Amoxicillin. Drugs R D 2007;8:395-399 (Pubitemid 350019433)
55. FDA Approves MiddleBrook's Moxatag - Amoxicillin PULSYS - for Pharyngitis/Tonsillitis in Adolescents and Adults. Drugs information online, 2008. Available from: http://www.drugs.com/newdrugs/fda-approves-middlebrook-s- moxatag-amoxicillin-pulsys-pharyngitis-tonsillitis-adolescents-adults-824.html. [Last accessed 9 January 2009]
56. A breakthrough in anti-infective therapy. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH-technology/ NOVEL-infectious.aspx. [Last accessed 24 January 2009]
57. A discovery that signals fundamental change. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH-technology/ default.aspx. [Last accessed 24 January 2009]
58. Keflex (Cephalexin, USP) products. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/PRODUCTS-antibiotics/KEFLEX- antibiotics.aspx. [Last accessed 25 January 2009]
59. The Middlebrook Pharmaceuticals, Inc Patent Strategy. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/ BREAKTHROUGH-technology/patents.aspx. [Last accessed 25 January 2009]
60. New antibiotics developments are on the horizon. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/PIPE- new-antibiotics/default.aspx. [Last accessed 25 January 2009]
61. Cha R, Rybak M. Pulsatile delivery of amoxicillin against Streptococcus pneumoniae. J Antimicrob Chemother 2004;54:1064-1071 (Pubitemid 40136743)
62. A proven difference. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH-technology/preclinical.aspx. [Last accessed 20 January 2009]
63. Redefining Infectious Disease therapy. The PULSYS technology platform. Middlebrook Pharmaceuticals, 2008. Available from: www.advancispharm.com/pdf/ pulsysproducts.pdf. [Last accessed 15 January 2009]
64. Our proprietary drug delivery technology PULSYS™. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/ BREAKTHROUGH-technology/TECH-drug-delivery.aspx. [Last accessed 24 January 2009]
65. Advancis Pharmaceutical Announces FDA Acceptance of Amoxicillin PULSYS NDA. Life Sciences world, 2008. Available from: http://www.lifesciencesworld. com/news/view/33928. [Last accessed 9 January 2009]
66. Newly approved drug therapies (977) Moxatag (amoxicillin). Middlebrook Pharmaceuticals, 2008. Available from: http://www.centerwatch.com/drug- information/fda-approvals/drug-details.aspx?DrugID=977. [Last accessed 11 January 2009]
67. Lan A, Colford J. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: A Meta-analysis. Pediatrics 2000;105:e19
68. Redesigning drugs to enhance performance. Verticaltalk. Pharma Focus Asia, 2008. Available from: http://www.pharmafocusasia.com/manufacturing/ redesigning-drugs.htm. [Last accessed 5 January 2009]
69. Flanner H, Treacy D, Beth B, et al. Modified release amoxicillin products. US20080132478; 2008
70. Rudnic E, Isbister J, Donald J, et al. Multiple delayed released antibiotic product, use and formulation thereof. US7025989; 2006
71. See how PULSYS works. Middlebrook Pharmaceuticals, 2008. Available from: http://www.middlebrookpharma.com/BREAKTHROUGH-technology/default.aspx. [Last accessed 18 January 2009]
72. Rudnic E, Isbister J, Treasy J, et al. Antiviral product, use and formulation thereof. US6541014; 2003 • PULSYS extended to antivirals and antifungals.
73. Moxatag approval a crucial first for Middlebrook. Breaking news on pharmaceutical technology, 2008. Available from: http://www.in- pharmatechnologist.com/Materials-Formulation/Moxatag-approval-a-crucial-first- for-MiddleBrook. [Last accessed 20 January 2009]